TransCode <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Amends Patent License Agreement with Massachusetts General Hospital, Increases Milestone Payments
TransCode Therapeutics Inc. announced it has entered into a Second Amendment to its Exclusive Patent License Agreement with The General Hospital Corporation, doing business as Massachusetts General Hospital. The amendment, effective August 15, 2025, updates the timelines for pre-sales requirements related to Patent Family 1 and Patent Family 2 under the agreement. Additionally, the aggregate amount of one-time milestone payments due to the licensor upon the achievement of certain milestones has been increased from $1,550,000 to $2,950,000 for each patent family. The specific amounts for therapeutic product- or process-related milestone payments were also revised. The full text of the amendment will be filed as an exhibit to TransCode Therapeutics' upcoming quarterly report.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-096658), on October 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.